Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that three abstracts featuring its investigational intravenous Deciparticle everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9-12 in San Antonio, Texas. The acceptance of multiple abstracts indicates significant scientific interest in this novel formulation, which represents a potential advancement in breast cancer treatment.
The investigational drug Sapu003, developed by Sapu Nano—a joint venture between Oncotelic and Dragon Oversea—is a novel intravenous formulation of everolimus specifically designed to overcome limitations of oral mTOR inhibitors such as Afinitor. Current oral formulations face challenges including poor bioavailability and restricted tumor penetration, which can limit their effectiveness in treating metastatic breast cancer. The abstracts scheduled for presentation will collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer patients.
This development is particularly important because HR⁺/HER2⁻ metastatic breast cancer represents a significant portion of breast cancer cases, and improved treatment options are continually needed. The intravenous formulation approach could potentially enhance drug delivery to tumor sites, improving therapeutic outcomes for patients who may not respond adequately to current oral therapies. The pharmacokinetic data to be presented will provide crucial insights into how the drug behaves in the body and its potential advantages over existing treatments.
The acceptance of these abstracts at a prestigious medical symposium like the San Antonio Breast Cancer Symposium underscores the scientific community's interest in novel approaches to cancer treatment. For investors and stakeholders, additional information about Oncotelic Therapeutics is available in the company's newsroom at https://ibn.fm/OTLC. The full press release containing detailed information about the abstract acceptances can be viewed at https://ibn.fm/Ut6V8.
As breast cancer remains one of the most common cancers affecting women worldwide, advancements in treatment formulations that address existing limitations could have substantial impact on patient care and outcomes. The Phase 1 trial data, when available, will be critical in determining whether this intravenous formulation represents a meaningful improvement over current standard treatments for metastatic breast cancer patients.
